ACTRN12614000548639已完成4 期
Effects of iron deficiency and its treatment on fibroblast growth factor 23 (FGF23) in patients treated with chronic haemodialysis therapy.
Eastern Health Integrated Renal Service0 个研究点目标入组 40 人开始时间: 2014年5月22日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •1. Aged 18-90 years
- •2. Receiving chronic thrice weekly haemodialysis therapy for >3 months
- •3. Requiring IV iron therapy based on current guidelines
排除标准
- •1. Inability to give informed consent
- •2. Active infection
- •3. Evidence of malignancy
- •4. Blood transfusion within preceding 4 weeks
- •5. Initial haemoglobin < 85 g/L
- •6. Previous hypersensitivity to intravenous iron sucrose or ferric carboxymaltose
- •7. Recent introduction or change in dose of erythropoietin agents, phosphate binders, vitamin D analogues or cinacalcet (within last 4 weeks)
研究者
相似试验
招募中
不适用
Does intravenous iron administration in pregnancy change blood vessel and heart function?ACTRN12616000173493yell McEwin Hospital15
尚未招募
Unknown
Iron deficiency in sickle cell diseaseCTRI/2024/01/061216ICMR
已完成
1 期
IRONWOMAN: the impact of iron deficiency in exercising womeIron deficiencyHaematological DisordersISRCTN14032359St Mary's University35
招募中
2 期
Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)diastolic heart failureNL-OMON54927Vrije Universiteit Medisch Centrum45
进行中（未招募）
1 期
Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)Heart failure with preserved ejection fractionEUCTR2019-003461-17-NLAmsterdam UMC, location VUmc45